Human medicines European public assessment report (EPAR): Vimkunya, Chikungunya vaccine (recombinant, adsorbed), Date of authorisation: 28/02/2025, Status: Authorised

Submitted by Anonymous (not verified) on 24 March 2025 - 10:30

Human medicines European public assessment report (EPAR): Vimkunya, Chikungunya vaccine (recombinant, adsorbed), Date of authorisation: 28/02/2025, Status: Authorised

Pilot on advice from expert panels to manufacturers of high-risk medical devices: Interim report on the experience with the pilot from February 2023 to December 2024

Submitted by Anonymous (not verified) on 24 March 2025 - 9:53

Pilot on advice from expert panels to manufacturers of high-risk medical devices: Interim report on the experience with the pilot from February 2023 to December 2024

EMA Veterinary Innovation Day, Online, European Medicines Agency, Amsterdam, the Netherlands, from 13 March 2025, 13:30 (CET) to 14 March 2025, 12:30 (CET)

Submitted by Anonymous (not verified) on 24 March 2025 - 9:15

EMA Veterinary Innovation Day, Online, European Medicines Agency, Amsterdam, the Netherlands, from 13 March 2025, 13:30 (CET) to 14 March 2025, 12:30 (CET)

Opinion/decision on a Paediatric investigation plan (PIP): Rinvoq, upadacitinib, decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), therapeutic area: Skin and subcutaneous tissue disorders, P

Submitted by Anonymous (not verified) on 21 March 2025 - 15:20

Opinion/decision on a Paediatric investigation plan (PIP): Rinvoq, upadacitinib, decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), therapeutic area: Skin and subcutaneous tissue disorders, PIP number: P/0062/2024

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Latest Newsletters

More